AUA 2011 - SBUR/SUO: Update on targeted therapies for advanced cancer - Session Highlights


WASHINGTON, DC USA ( - Regarding targeted therapies for advanced renal cell cancer, Dr. Pantuck showed the therapeutic time line of new discoveries over the past 30 years.

Sutent showed better progression-free survival compared with immunotherapy in 2005. In, 2008 data showed a median overall survival of 26 months. There are presently 7 different options for advanced renal cell cancer. First line choice of agents is based upon risk stratification with temsirolimus used for poor risk patients. Second line drug selection depends on what mechanism was targeted in the first line therapy.

There are several new agents showing promise as first and second line therapy. Sequential rather than combination therapy is often applied, and this has implications for toxicities. Since the shift from IL-2 to targeted therapies, we lose the benefit if the 5-10% of complete responders.

Kidney cancer has evolved from a disease with few treatment options to one with many choices but this is more quantitative rather than qualitative. If complete tumor response is the goal, then surgery remains an important component of treatment.



Presented by Allan Pantuck, MD at the Society for Basic Urologic Research (SBUR)/Society of Urologic Oncology (SUO) joint meeting during the American Urological Association (AUA) Annual Meeting - May 14 - 19, 2011 - Walter E. Washington Convention Center, Washington, DC USA

Reported for UroToday by Christopher P. Evans, MD, FACS, Professor and Chairman, Department of Urology, University of California, Davis, School of Medicine.


The opinions expressed in this article are those of the Contributing Editor and do not necessarily reflect the viewpoints of the SPU or the American Urological Association.



View Full AUA 2011 Meeting Coverage

email news signup